Methoxy Polyethylene Glycol-Epoetin Beta
Recommended · restricted HaematologyRestricted
Treatment of anaemia requiring transfusion (haemoglobin <100 g/L) where intrinsic renal disease, as assessed by a nephrologist, is the primary cause, in patients with chronic kidney disease.
1
Submissions
2009–09
On the record
—
ICER range
Cost-min
Cost basis
Access path
- Nov 2009Recommended · restricted
vs darbepoetin alfa
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost minimisation analysis presented; no ICER calculated as submission was based on equi-effective dosing.
The PBAC recommended that the cost per day for the Erythropoeisis Stimulating Agents (ESAs) should be the same, taking into account the different settings of use. PBAC · 2009
Decision context
PopulationPatients with anaemia of chronic kidney disease (CKD), including pre-dialysis patients, patients new to dialysis, and patients already on treatment with an existing erythropoiesis stimulating agent (ESA).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2009 | Recommended · restricted | darbepoetin alfa | — | RCT |